The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine

Pharmacogenetics

Volumn 9, Issue 1, 1999, Pages 55-60

  Fjordsid, Lene ^a,c   Jeppesen, Unni ^a   Eap, C B ^b   Powell, K ^b   Baumann, Pierre ^b   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^c Institute of Medical Biology   (Denmark)

Author keywords

Cytochrome P450 CYP2D6; Fluoxetine; Genetic polymorphisms; Stereoselectivity

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; FLUOXETINE; FONTEX; NORFLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SPARTEINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; STEREOCHEMISTRY;

EID: 0032891488     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199902000-00008     Document Type: Article

References (14)

1. Brosen K, Skjelbo E, Fluoxetine and norfluoxetine are potent inhibitors of P450 HD6 - the source of the sparteine/debrisoquine oxidation polymorphism [letter]. Br J Clin Pharmacol 1991; 32:136-137.
2. Brosen K, Rasmussen BB, Feighner JP, Boyer WF, editors. Selective scrotonin re-uptake inhibitors: pharmacokinetics and drug interactions. In: Selective serotonin re-uptake inhibitors: advances in basic research and clinical practice, 2nd edn. Chichester: Jolin Wiley & Sons Ltd; 1996: pp. 85-105.
3. Eap CB, Gaillard N, Powell K, Baumann P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography mass spectrometry. Journal Chromatogr B: Biomed Appl 1996; 682:265-272.
4. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as scrotonin uptake inhibitors in vivo. Neuropharmacology 1992; 31:997-1000.
5. Gram L. Fluoxetine. N Engl J Med 1994; 331:1354-1361.
6. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, Lebel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Therapeut 1996; 60:512-521.
7. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46:14-19.
8. Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation [letter]. J Clin Psychopharmacol 1991; 11:224-225.
9. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266:964-971.
10. Torok Both GA, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatogr Biomed Appl 1992; 579:99-106.
11. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988; 145:1478.
12. Vinks A, Inaba T, Otton SV, Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982; 31:23-29.
13. Wong DT, Fuller RW, Robertson DW. Fluoxetine and its two enantiomers as selective serotonin reuptake inhibitors. Acta Pharm Nord 1990; 2:171-180.
14. Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushinski JH, Robertson DW. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacology 1993; 8:337-344.